OptiNose (OPTN) – StreetInsider.com Reports
-
Optinose (OPTN) PT Raised to $4 at Lake Street Capital Markets
-
OptiNose (OPTN) Announces XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
-
OptiNose (OPTN) Halted, News Pending
-
H.C. Wainwright Starts Optinose (OPTN) at Buy
-
OptiNose (OPTN) Reports In-Line Q4 EPS, provides guidance
-
OptiNose (OPTN) Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
-
OptiNose (OPTN) Tops Q3 EPS by 1c
-
Lake Street Capital Markets Starts Optinose (OPTN) at Buy, 'potential label-expanding FDA approval in December could triple the TAM'
-
OptiNose (OPTN) Files $200M Mixed Shelf
-
OptiNose (OPTN) Tops Q2 EPS by 13c
-
OptiNose (OPTN) Reports Prelim Q2 XHANCE Net Revenue of $19.5M
-
OptiNose (OPTN) Misses Q1 EPS by 1c; Offers FY23 Guidance
-
OptiNose (OPTN) Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
-
Optinose (OPTN) PT Lowered to $4 at BMO Capital
-
OptiNose (OPTN) Tops Q4 EPS by 2c
-
OptiNose (OPTN) Submits Supplemental New Drug Application for XHANCE Label Expansion
-
OptiNose (OPTN) Appoints Paul Spence as Chief Commercial Officer
-
OptiNose (OPTN) Announces Departure of Acting Chief Financial Officer
-
OptiNose (OPTN) Prices 26.32M Share and Warrant Offering at $1.90/sh
-
OptiNose (OPTN) Announced Proposed Stock Offering
-
Optinose (OPTN) PT Lowered to $5 at BMO Capital
-
Optinose (OPTN) PT Lowered to $5 at BMO Capital
-
OptiNose (OPTN) Tops Q3 EPS by 1c
-
Jefferies Assumes Optinose (OPTN) at Buy
-
Optinose (OPTN) PT Raised to $5 at Piper Sandler
-
OptiNose (OPTN) Tops Q2 EPS by 1c
-
OptiNose (OPTN) Reports Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
-
OptiNose (OPTN) Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
-
OptiNose (OPTN) Announces CFO Departure
-
OptiNose (OPTN) Appoints R. John Fletcher to its Board
-
Optinose (OPTN) PT Lowered to $8 at BMO Capital
-
OptiNose (OPTN) to Resume Trading at 7:30 a.m.
-
OptiNose (OPTN) announces XHANCE met both co-primary endpoints in the ReOpen1 trial
-
OptiNose (OPTN) Halted, News Pending
-
OptiNose (OPTN) Appoints Eric Bednarski and Kyle Dempsey to its Board
-
Optinose (OPTN) PT Lowered to $6 at Piper Sandler
-
Optinose (OPTN) PT Lowered to $9 at BMO Capital
-
Optinose (OPTN) PT Lowered to $9 at Cowen
-
Pre-Open Stock Movers 11/16: (KZR) (AXON) (RMO) Higher; (BODY) (OPTN) (CLOV) Lower (more...)
-
OptiNose (OPTN) Prices 25M Share Offering at $1.60/sh
-
After-Hours Stock Movers 11/15: (AXON) (RMO) (RPRX) Higher; (BODY) (OPTN) (CLOV) Lower (more...)
-
OptiNose (OPTN) Announces Proposed Public Offering of Common Stock
-
OptiNose (OPTN) Files 14.27M Share Offering
-
Optinose (OPTN) Full Year Target Not Only Achievable, But Likely Conservative - Analyst
-
Optinose (OPTN) PT Lowered to $10 at RBC Capital
-
OptiNose (OPTN) Tops Q1 EPS by 4c, Revenues Beat
-
RBC Capital Assumes Optinose (OPTN) at Outperform
-
Optinose (OPTN) PT Lowered to $16 at BMO Capital
-
Optinose (OPTN) PT Lowered to $18 at BMO Capital
-
OptiNose (OPTN) Announces Preliminary Q3 XHANCE Net Revenue of $15.4 Million
Back to OPTN Stock Lookup